The efficacy and safety of rivaroxaban in patients with atrial fibrillation undergoing elective cardioversion — the results of X-VeRT trial

Abstract

X-VeRT trial is the first prospective randomised trial evaluating the efficacy and safety of a novel oral anticoagulant — rivaroxa­ban — compared with vitamin K antagonist therapy in patients undergoing elective cardioversion. The study showed a similar risk of the primary endpoint in both groups, both in terms of efficacy and safety. However, rivaroxaban was associated with significantly shorter time to cardioversion compared with vitamin K antagonists (p < 0.001). Based on data from X-VeRT trial, rivaroxaban can be regarded as an effective and safe alternative to vitamin K antagonists in patients with atrial fibrillation scheduled for cardioversion, regardless of strategy type.